Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | OXTR | P30559 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | IDH1 | O75874 | 2/20 | 0.32 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.31 |
| ▸ | ITGAV | P06756 | 3/20 | 0.31 |
| ▸ | JMJD6 | Q6NYC1 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.30 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.30 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.30 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.30 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.30 |
| ▸ | FDPS | P14324 | 1/20 | 0.30 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20153309 | 0.88 | KDM4E (0.35) | KDM4EALDH1A1HTTOXTRLMNA | |
| SCHEMBL20153326 | 0.82 | KDM4E (0.40) | KDM4EALDH1A1HTTOXTRLMNA | |
| SCHEMBL21311520 | 0.80 | ITGB3 (0.37) | KDM4EALDH1A1HTTOXTRLMNA | |
| SCHEMBL20153311 | 0.80 | ITGB3 (0.36) | ITGB3ITGAVITGB1ITGA5 | |
| SCHEMBL21311585 | 0.80 | OXTR (0.36) | KDM4EALDH1A1HTTOXTRLMNA | |
| SCHEMBL20153312 | 0.76 | ITGAV (0.57) | ITGB3ITGAVITGB1ITGA5 | |
| SCHEMBL23747238 | 0.76 | ITGB3 (0.34) | KDM4EALDH1A1HTTOXTRLMNA | |
| SCHEMBL21311744 | 0.76 | ITGB3 (0.34) | KDM4EALDH1A1HTTOXTRLMNA | |
| SCHEMBL21317461 | 0.76 | KDM4E (0.32) | KDM4EALDH1A1HTTOXTRLMNA | |
| SCHEMBL28744166 | 0.76 | ITGB3 (0.35) | KDM4EALDH1A1HTTOXTRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3538525-B1 | 3-SUBSTITUTED PROPIONIC ACIDS AS ALPHA V INTEGRIN INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2022-06-22 | — | — | EP | disclosed |
| US-20210188847-A1 | 3-SUBSTITUTED PROPIONIC ACIDS AS ALPHA V INTEGRIN INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-06-24 | — | — | US | disclosed |
| US-10968219-B2 | 3-substituted propionic acids as αV integrin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-04-06 | — | — | US | disclosed |
| US-20190263808-A1 | 3-SUBSTITUTED PROPIONIC ACIDS AS ALPHA V INTEGRIN INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-08-29 | — | — | US | disclosed |
| WO-2018089353-A1 | 3-SUBSTITUTED PROPIONIC ACIDS AS ALPHA V INTEGRIN INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190263808-A1 | 3-SUBSTITUTED PROPIONIC ACIDS AS ALPHA V INTEGRIN INHIBITORS | ITGAV, ITGB3, ITGB1 | KDM4E 1484/4885ALDH1A1 491/4885HTT 4418/4885 |
| US-20210188847-A1 | 3-SUBSTITUTED PROPIONIC ACIDS AS ALPHA V INTEGRIN INHIBITORS | ITGAV, ITGB3, ITGB1 | KDM4E 2771/4885ALDH1A1 545/4885HTT 4257/4885 |
| US-10968219-B2 | 3-substituted propionic acids as αV integrin inhibitors | ITGB3, ITGB1, ITGAV | KDM4E 1796/4885ALDH1A1 431/4885HTT 4490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.